IMPALA-2 A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) SAV006-05 Site 38
Administered By
Awarded By
Contributors
- Bergin, Stephen Patrick Principal Investigator
Start/End
- August 13, 2021 - November 30, 2024